Stryker Stock Hits New 52-Week High (SYK)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Stryker Corporation (NYSE: SYK) hit a new 52-week high Tuesday as it is currently trading at $66.62, above its previous 52-week high of $66.57 with 604,040 shares traded as of 1:40 p.m. ET. Average volume has been 1.8 million shares over the past 30 days.

Stryker has a market cap of $25.01 billion and is part of the health care sector and health services industry. Shares are up 20.8% year to date as of the close of trading on Monday.

Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. The company has a P/E ratio of 19.4, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Stryker as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Stryker Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

These Stocks Are Ready to Reverse Course

Don't Get Out of Joint

Zimmer Biomet: Cramer's Top Takeaways

Market Stands at a Make-Or-Break Level: Cramer's 'Mad Money' Recap (Monday 7/17/17)

Analyst Says Rival Bidder Could Emerge for Novadaq After Stryker Deal